Three-dimensional quantitative structure-activity relationships of ATP-sensitive potassium (KATP) channel openers belonging to the 3-alkylamino-4H-1,2,4-benzo- and 3-alkylamino-4H-1,2,4-pyridothiadiazine 1,1-dioxide families

Journal of Medicinal Chemistry

Volumn 49, Issue 23, 2006, Pages 6779-6788

  De Tullio, Pascal ^a   Dupont, Léon ^a   Francotte, Pierre ^a   Counerotte, Stéphane ^a   Lebrun, Philippe ^b   Pirotte, Bernard ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4H 1,2,4 PYRIDOTHIADIAZINE 1,1 DIOXIDE DERIVATIVE; ADENOSINE TRIPHOSPHATE; POTASSIUM CHANNEL STIMULATING AGENT; PYRIDINE DERIVATIVE; THIADIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

AORTA; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; MOLECULAR MODEL; PANCREAS; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

ADENOSINE TRIPHOSPHATE; ANIMALS; AORTA; CYCLIC S-OXIDES; INSULIN; ION CHANNEL GATING; ISLETS OF LANGERHANS; MODELS, MOLECULAR; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; POTASSIUM CHANNELS; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; THIADIAZINES;

EID: 33751006447     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060534w     Document Type: Article

References (45)

1. + channels in cardiac muscle. Nature 1983, 305, 147-148.
2. + channels in pancreatic B-cells. Nature 1984, 311, 271-273.
3. + channel. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 9816-9820.
4. + channels in arterial smooth muscle. Science 1989, 245, 177-180.
5. + channels in mammalian skeletal muscle cells. Eur. J. Pharmacol. 1993, 236, 419-426.
6. Quayle, J. M.; Nelson, M. T.; Standen, N. B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev. 1997, 77, 1165-1232.
7. Bryan, J.; Aguilar-Bryan, L. The ABCs of ATP-sensitive potassium channels: More pieces of the puzzle. Curr. Opin. Cell Biol. 1997, 9, 553-559.
8. + channels. Prog. Biophys. Mol. Biol. 2003, 81, 133-176.
9. ATP channels. Annu. Rev. Physiol. 1998, 60, 667-687.
10. + channel openers. Mol. Pharmacol. 1999, 56, 308-315.
11. Seino, S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu. Rev. Physiol. 1999, 61, 337-362.
12. KATP: An inward rectifier subunit plus a sulfonylurea receptor. Science 1995, 270, 1166-1170.
13. + channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: Opposite effects of MgADP. Mol. Pharmacol. 1999, 55, 832-840.
14. + channels plays a crucial role in the control of insulin secretion. Pflüegers Arch. 1989, 414, S115-S120.
15. Lebrun, P. Flux cationiques dans les cellules B des îlots pancréatiques et investigations pharmacologiques. Rev. Fr. Endocrinol. Clin. 1993, 34, 241-254.
16. Kolb, H. A. Potassium channels in excitable and non-excitable cells. Rev. Physiol. Biochem. Pharmacol. 1990, 15, 51-79.
17. ATP channels in vascular smooth muscles. Clin. Exp. Pharmacol. Physiol. 2002, 29, 312-316.
18. + channels. Prog. Biophys. Mol. Biol. 2003, 81, 133-176.
19. Coghlan, M. J.; Carroll, W. A.; Gopalakrishnan, M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: Update from a decade of progress. J. Med. Chem. 2001, 44, 1627-1653.
20. Lebrun, P.; Devreux, V.; Hermann, M.; Herchuelz, A. Similarities between the effects of pinacidil and diazoxide on ionic and secretory events in rat pancreatic islets. J. Pharmacol. Exp. Ther. 1989, 250, 1011-1018.
21. + channels? Trends Pharmacol. Sci. 1993, 14, 332-337.
22. ATP channel openers: Structure-activity relationships and therapeutic potential. Med. Res. Rev. 2004, 24, 213-266.
23. Björk, E,; Berne, C.; Kämpe, O.; Wibell, P.; Oskarsson, P.; Karlsson, F. A. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996, 45, 1427-1430,
24. Alemzadeh, R.; Langley, G.; Upchurch, L.; Smith, P.; Slonim, A. E. Beneficial effect of diazoxide in obese hyperinsulinemic adults. J. Clin. Endocrinol. Metab. 1998, 83, 1911-1915.
25. Rasmussen, S. B.; Sorensen, T. S.; Hansen, J. B.; Mandrup-Poulsen, T.; Hornum, L.; Markholst, H. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cells function and mass in acutely diabetic BB rats. Horm. Metab. Res. 2000, 32, 294-300.
26. Ritzel, R. A.; Hansen, J. B.; Veldhuis, J. D.; Butler, P. C. Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. J. Clin. Endocrinol. Metab. 2004, 89, 795-805.
27. Kumar, G. K.; Dastoor, F. C.; Robayo, J. R.; Razzaque, M. A. Side effects of diazoxide. JAMA, J. Am. Med. Assoc. 1976, 235, 275-276.
28. de Tullio, P.; Pirotte, B.; Lebrun, P.; Fontaine, J.; Dupont, L.; Antoine, M.-H.; Ouedraogo, R.; Khelili, S.; Maggetto, C.; Masereel, B.; Diouf, O.; Podona, T.; Delarge, J. 3- and 4-Substituted 4H-pyrido[4,3-e]-1,2,4- thiadiazine 1,1-dioxides as potassium channel openers: Synthesis, pharmacological evaluation and structure-activity relationships. J. Med. Chem. 1996, 39, 937-948.
29. de Tullio, P.; Ouedraogo, R.; Dupont, L.; Somers, F.; Boverie, S.; Dogné, J.-M.; Delarge, J.; Pirotte, B. Synthesis and structural studies of 3-alkylamino-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides, a new class of heterocyclic compounds with therapeutic promises. Tetrahedron 1999, 55, 5419-5432.
30. Pirotte, B.; Ouedraogo, R.; de Tullio, P.; Khelili, S.; Somers, F.; Boverie, S.; Dupont, L.; Fontaine, J.; Damas, J.; Lebrun, P. 3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: Design, synthesis, and pharmacological evaluation. J. Med. Chem. 2000, 43, 1456-1466.
31. Boverie, S.; Antoine, M.-H.; de Tullio, P.; Somers, F.; Becker, B.; Sebille, S.; Lebrun, P.; Pirotte, B. Effect on insulin release of compounds structurally related to the potassium-channel opener 7-chloro-3-isopropylamino- 4H-1,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73): Introduction of heteroatoms on the 3-alkylamino side chain of the benzothiadiazine 1,1-dioxide ring. J. Pharm. Pharmacol. 2001, 53, 973-980.
32. 2+ channel blockers? Biol. Chem. 2002, 383, 1759-1768.
33. ATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides. J. Med. Chem. 2003, 46, 3342-3353.
34. ATP channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4- benzothiadiazine 1,1-dioxides. J. Med. Chem. 2005, 48, 3492-3503.
35. de Tullio, P.; Boverie, S.; Becker, B.; Antoine, M.-H.; Nguyen, Q.-A.; Francotte, P.; Counerotte, S.; Sebille, S.; Pirotte, B.; Lebrun, P. 3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: Effect of 6,7-disubstitution on potency and tissue selectivity. J. Med. Chem. 2005, 48, 4990-5000.
36. + channels. Biochem. Pharmacol. 1994, 47, 1381-1386.
37. + channels and inhibiting insulin release. Diabelologia 2000, 43, 723-732.
38. Cosgrove, K.; Antoine, M.-H.; Lee, A.; Barnes, P.; de Tullio, P.; Clayton, P.; McCloy, R.; De Lonlay, P.; Nihoul-Fékété, C.; Robert, J.; Saudubray, J.-M.; Rahier, J.; Lindley, K.; Hussain, K.; Aynsley-Green, A.; Pirotte, B.; Lebrun, P.; Dunne, M. BPDZ 154 activates adenosine 5′-triphosphate-sensitive potassium channels: In vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism. J. Clin. Endocrinol. Metab. 2002, 87, 4860-4868.
39. Dabrowski, M.; Ashcroft, F. M.; Ashfield, R.; Lebrun, P.; Pirotte, B.; Egebjerg, J.; Hansen J. B.; Wahl, P. The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener. Diabetes 2002, 51, 1896-1906.
40. Nielsen, F. E.; Bodvarsdottir, T. B.; Worsaae, A.; MacKay, P.; Stidsen, C. E.; Boonen, H. C.; Pridal, L.; Arkhammar, P. O. G.; Whal, P.; Ynddal, L.; Junager, F.; Dragsted, N.; Tagmose, T. M.; Mogensen, J. P.; Koch, A.; Treppendahl, S. P.; Hansen, J. B. 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4- benzothiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells. J. Med. Chem. 2002, 45, 4171-4187.
41. Pirotte, B.; de Tullio, P.; Antoine, M.-H.; Sebille, S.; Florence, X.; Lebrun, P. New insights into the development of ATP-sensitive potassium channel openers. Expert Opin. Ther. Patents 2005, 15, 497-504.
42. Sybyl 7.0; Tripos Associates, Inc.: St. Louis, MO, 2004.
43. Stewart, J. J. MOPAC, a Semiempirical Molecular Orbital Program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
44. Khelili, S.; de Tullio, P.; Lebrun, P.; Fillet, M.; Antoine, M.-H.; Ouedraogo, R.; Dupont, L.; Fontaine, J.; Felekidis, A.; Leclerc, G.; Delarge, J.; Pirotte, B. Preparation and pharmacological evaluation of the R- and S-enantiomers of 3-(2′-butylamino)-4H- and 3-(3′-methyl-2- butylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide, two tissue selective ATP-sensitive potassium channel openers. Bioorg. Med. Chem. 1999, 7, 1513-1520.
45. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.